[go: up one dir, main page]

HUP0004646A2 - IL-8 receptor antagonista hatású benzizotiazolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

IL-8 receptor antagonista hatású benzizotiazolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0004646A2
HUP0004646A2 HU0004646A HUP0004646A HUP0004646A2 HU P0004646 A2 HUP0004646 A2 HU P0004646A2 HU 0004646 A HU0004646 A HU 0004646A HU P0004646 A HUP0004646 A HU P0004646A HU P0004646 A2 HUP0004646 A2 HU P0004646A2
Authority
HU
Hungary
Prior art keywords
cr8r8
alkenyl
group
aryl
alkyl
Prior art date
Application number
HU0004646A
Other languages
English (en)
Inventor
Hong Nie
Katherine L. Widdowson
Original Assignee
Smithkline Beecham Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp. filed Critical Smithkline Beecham Corp.
Publication of HUP0004646A2 publication Critical patent/HUP0004646A2/hu
Publication of HUP0004646A3 publication Critical patent/HUP0004646A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány (I) általános képletű vegyületekre - amelyek képletében aszubsztituensek főbb jelentései R -NH-C(X)-NH-(CR13R14)v-Z csoport; ZW, adott esetben szubsztituált heteroaril-, cikloalkil-, alkil-,alkenil- vagy alkinilcsoport; X oxo- vagy tioxocsoport; A -CR20R21csoport; R1 hidrogén-, halogénatom, nitro-, ciano-, halogén-alkil-,alkil-, alkenil-, alkoxi-, halogén-alkoxi-, azido-, -(CR8R8)qS(O)tR4,hidroxi-, hidroxi-alkil-, aril-, aril-alkil-, aril-oxi-, aril-alkoxi-,heteroaril-, heteroaril-alkil-, heterociklil-, heterociklil-alkil-,heteroaril-alkoxi-, aril-alkenil-, heteroaril-alkenil-, heterociklil-alkenil-, -(CR8R8)qNR4R5, -alkenil-C(O)NR4R5, -(CR8R8)qC(O)NR4R5, -(CR8R8)qC(O) NR4R10, -S (O)3R8, -(CR8R8)qC(O)R11, -alkenil-C(O)R11, -alkenil-C(O)OR11. -C(O)R11, -(CR8R8)qC(O)OR12, -(CR8R8)qOC(O)R11 -(CR8R8)qNR4C(O)R11, -(CR8R8)qC(NR4)NR4R5, -(CR8R8)qNR4C(NR5)Rll, -(CR8R8)qNHS(O)2R17 vagy -(CR8R8)qS(O)2NR4R5 csoport; vagy két R1csoport együtt -O-(CH2)S-O- csoportot vagy egy ciklusos csoportotképezhet; n, m és s értéke 1, 2 vagy 3; q értéke 0, 1, 2, 3, 4, 5, 6,7, 8, 9 vagy 10; t értéke. 0, 1 vagy v értéke 0, 1, 2, 3 vagy 4; Wjelentése E adott esetben csoport, ahol a csillagok (*) a gyűrűkapcsolódási pontjait jelzik - és a vegyületeket tartalmazó, IL-8avagy IL-8< receptorhoz kötődő kemokin által mediált betegségekkezelésére szolgáló gyógyszerkészítményekre vonatkozik. Ó
HU0004646A 1997-09-05 1998-09-04 Il-8 receptor antagonist benzisothiazole derivatives, process for their preparation and pharmaceutical compositions containing them HUP0004646A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5799897P 1997-09-05 1997-09-05
PCT/US1998/018569 WO1999011264A1 (en) 1997-09-05 1998-09-04 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
HUP0004646A2 true HUP0004646A2 (hu) 2001-09-28
HUP0004646A3 HUP0004646A3 (en) 2002-12-28

Family

ID=22014023

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004646A HUP0004646A3 (en) 1997-09-05 1998-09-04 Il-8 receptor antagonist benzisothiazole derivatives, process for their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
US (1) US6297265B2 (hu)
EP (1) EP1003509A4 (hu)
JP (1) JP2001514225A (hu)
KR (1) KR20010023672A (hu)
CN (1) CN1278726A (hu)
AR (1) AR015425A1 (hu)
AU (1) AU732728B2 (hu)
BR (1) BR9812176A (hu)
CA (1) CA2302450A1 (hu)
CO (1) CO4970747A1 (hu)
HU (1) HUP0004646A3 (hu)
IL (1) IL134855A0 (hu)
NO (1) NO20001100L (hu)
PL (1) PL339134A1 (hu)
TR (1) TR200000611T2 (hu)
WO (1) WO1999011264A1 (hu)
ZA (1) ZA988100B (hu)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR008331A1 (es) * 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
PE20011124A1 (es) 2000-03-31 2001-10-28 Upjohn Co Nuevos agentes antibacterianos de benzosultam oxazolidinona
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
WO2002043758A2 (en) * 2000-12-01 2002-06-06 Schering Corporation Uses of mammalian genes and related reagents
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CN1599734A (zh) * 2001-10-12 2005-03-23 先灵公司 作为cxc趋化因子受体拮抗剂的3,4－二取代的马来酰亚胺化合物
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
CA2479126C (en) * 2002-03-18 2011-11-15 Schering Corporation Combination treatments for chemokine-mediated diseases
WO2004033440A1 (en) * 2002-10-09 2004-04-22 Schering Corporation Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
DE10345403A1 (de) * 2003-09-30 2005-04-28 Infineon Technologies Ag Material und Zellenaufbau für Speicheranwendungen
JP4939229B2 (ja) * 2003-12-19 2012-05-23 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール
MXPA06007205A (es) * 2003-12-22 2006-08-31 Schering Corp Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimiocina.
KR20070011475A (ko) 2004-05-12 2007-01-24 쉐링 코포레이션 Ｃｘｃｒ1 및 ｃｘｃｒ2 케모카인 길항제
US20070249625A1 (en) * 2004-10-20 2007-10-25 Jakob Busch-Petersen Il-8 Receptor Antagonists
EP1907399B1 (en) * 2005-06-29 2010-10-27 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
US7718678B2 (en) * 2005-06-29 2010-05-18 Schering Corporation Di-substituted oxadiazoles as CXC-chemokine receptor ligands
WO2007124423A2 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
AU2007240365B2 (en) * 2006-04-21 2011-12-15 Glaxosmithkline Llc IL-8 receptor antagonists
CL2007001829A1 (es) * 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
TW200813033A (en) * 2006-07-07 2008-03-16 Schering Corp 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor ligands
UA124308C2 (uk) * 2016-07-04 2021-08-25 Байєр Кропсайєнс Акцієнгезелльшафт Бензосультами й аналоги і їх застосування як фунгіцидів
JP7228675B2 (ja) 2018-08-16 2023-02-24 イー・エム・デイー・ミリポア・コーポレイシヨン 閉鎖バイオプロセシングデバイス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
AU683387B2 (en) 1994-06-08 1997-11-06 E.I. Du Pont De Nemours And Company Cyclic sulfonamide herbicides
JP3720395B2 (ja) * 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
USRE38970E1 (en) * 1995-10-05 2006-02-07 Kyoto Pharmaceutical Industries, Ltd. Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors
AR008331A1 (es) * 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists

Also Published As

Publication number Publication date
AR015425A1 (es) 2001-05-02
TR200000611T2 (tr) 2000-08-21
CO4970747A1 (es) 2000-11-07
KR20010023672A (ko) 2001-03-26
ZA988100B (en) 1999-03-05
PL339134A1 (en) 2000-12-04
NO20001100D0 (no) 2000-03-03
HUP0004646A3 (en) 2002-12-28
EP1003509A4 (en) 2002-11-20
IL134855A0 (en) 2001-05-20
WO1999011264A1 (en) 1999-03-11
BR9812176A (pt) 2001-12-18
CN1278726A (zh) 2001-01-03
US20010018447A1 (en) 2001-08-30
JP2001514225A (ja) 2001-09-11
US6297265B2 (en) 2001-10-02
NO20001100L (no) 2000-03-03
AU9566398A (en) 1999-03-22
EP1003509A1 (en) 2000-05-31
AU732728B2 (en) 2001-04-26
CA2302450A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
HUP0004646A2 (hu) IL-8 receptor antagonista hatású benzizotiazolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
NO20073257L (no) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
HUP0003581A2 (hu) IL-8 receptor antagonista hatású benzizotiazolszármazékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0302167A2 (hu) Metabotropikus glutamát receptor antagonista hatású kinolinszármazékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
BRPI0407504A (pt) heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
ATE214709T1 (de) 14,15-cyclopropanosteroide der 19-norandrostan- reihe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
NO20061406L (no) Organiske forbindelser
NO20085077L (no) Nye forbindelser
ATE327229T1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
NO20020282D0 (no) Nytt difenylpiperidinderivat
HUP0204011A2 (en) 1,2-diaryl benzimidazoles, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions for treating illnesses associated with a microglia activation
NO20091766L (no) Spiro-piperidinderivater
NO20083583L (no) Heterosykliske antivirale forbindelser
HUP0203429A2 (hu) Immunmodulátor szteroidok és különösen a 16-alfa-brómepiandroszteron-hemihidrát, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE50311923D1 (de) Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
SE9902551D0 (sv) Novel compounds
TW200517382A (en) Imidazole derivatives
DE50204789D1 (de) Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
NO20092264L (no) Spiro-piperidinderivater
NO20091830L (no) Spiro-piperidinderivater som VIa reseptorantagonister